- Home
- BEDU vs MRSN Comparison
BEDU vs MRSN Comparison
Compare BEDU & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEDU
- MRSN
- Stock Information
- Founded
- BEDU 1994
- MRSN 2001
- Country
- BEDU United Kingdom
- MRSN United States
- Employees
- BEDU N/A
- MRSN N/A
- Industry
- BEDU Other Consumer Services
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- BEDU Real Estate
- MRSN Health Care
- Exchange
- BEDU Nasdaq
- MRSN Nasdaq
- Market Cap
- BEDU 44.9M
- MRSN 36.4M
- IPO Year
- BEDU 2017
- MRSN 2017
- Fundamental
- Price
- BEDU $1.48
- MRSN $0.35
- Analyst Decision
- BEDU
- MRSN Buy
- Analyst Count
- BEDU 0
- MRSN 3
- Target Price
- BEDU N/A
- MRSN $4.00
- AVG Volume (30 Days)
- BEDU 24.4K
- MRSN 3.1M
- Earning Date
- BEDU 04-29-2025
- MRSN 05-08-2025
- Dividend Yield
- BEDU N/A
- MRSN N/A
- EPS Growth
- BEDU N/A
- MRSN N/A
- EPS
- BEDU N/A
- MRSN N/A
- Revenue
- BEDU $231,461,038.00
- MRSN $40,497,000.00
- Revenue This Year
- BEDU N/A
- MRSN N/A
- Revenue Next Year
- BEDU N/A
- MRSN N/A
- P/E Ratio
- BEDU N/A
- MRSN N/A
- Revenue Growth
- BEDU N/A
- MRSN 9.88
- 52 Week Low
- BEDU $1.35
- MRSN $0.26
- 52 Week High
- BEDU $2.42
- MRSN $3.83
- Technical
- Relative Strength Index (RSI)
- BEDU 40.48
- MRSN 44.90
- Support Level
- BEDU $1.50
- MRSN $0.31
- Resistance Level
- BEDU $1.78
- MRSN $0.40
- Average True Range (ATR)
- BEDU 0.22
- MRSN 0.05
- MACD
- BEDU -0.03
- MRSN 0.01
- Stochastic Oscillator
- BEDU 5.38
- MRSN 68.09
About BEDU Bright Scholar Education Holdings Limited each representing four
Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom (the UK) and the United States (the U.S.) Kingdom. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.